RecruitingPhase 1NCT06730386

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors

Sponsor

Akeso

Enrollment

100 participants

Start Date

Feb 24, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Cancer

Summary

This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AK138D1 for people with solid cancer. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAK138D1

Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.

Locations(4)

Blacktown Hospital-Blacktwon Cancer and Haematology Centre

Blacktown, New South Wales, Australia

Macquarie University

North Ryde, New South Wales, Australia

ICON Cancer Centre South Brisbane

South Brisbane, Queensland, Australia

Peninsula & South Eastern Haematology and Oncology Group

Frankston, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06730386

Related Trials

Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)

NCT067970371 location

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025146 locations

TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors

NCT072424172 locations

Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors

NCT071613101 location

Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors

NCT072581601 location